$ 2.36
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Strong growth
About
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, overprice
Target Price
The average target price of PROK is 5.7 and suggests 140% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
